although
virus
known
second
common
etiolog
factor
communityacquir
pneumonia
cap
respiratori
viral
profil
patient
healthcareassoci
pneumonia
hcap
yet
elucid
investig
preval
clinic
impact
respiratori
viru
infect
adult
patient
hcap
patient
admit
hcap
cap
januari
decemb
tertiari
referr
hospit
korea
prospect
enrol
viru
identif
perform
use
reversetranscript
polymeras
chain
reaction
rtpcr
among
enrol
patient
hcap
cap
sampl
respiratori
virus
collect
sputum
endotrach
aspir
patient
nasopharyng
specimen
patient
eightyseven
patient
viral
infect
proport
viral
infect
significantli
lower
hcap
cap
group
vs
p
hcap
cap
group
influenza
common
respiratori
viru
follow
enterorhinoviru
season
distribut
respiratori
virus
also
similar
group
hcap
group
viral
infect
result
similar
length
hospit
stay
inhospit
mortal
viralbacteri
coinfect
bacteri
infect
cap
group
show
similar
result
conclus
patient
increasingli
receiv
treatment
facil
hospit
includ
longterm
health
care
facil
due
rapidli
increas
age
popul
often
chronic
diseas
pneumonia
occur
prior
hospit
admiss
patient
recent
contact
health
system
term
healthcareassoci
pneumonia
hcap
patient
believ
increas
risk
infect
multidrugresist
mdr
organ
particular
concern
hcap
patient
howev
recent
studi
indic
mani
patient
defin
hcap
infect
mdr
pathogen
even
exclud
mdr
pathogen
substanti
differ
etiolog
profil
communityacquir
pneumonia
cap
hcap
group
note
recent
studi
indic
hcap
set
might
present
uniqu
risk
pneumonia
incid
viral
pneumonia
increas
past
decad
part
appar
increas
reflect
improv
diagnost
techniqu
includ
polymeras
chain
reaction
pcr
last
decad
sever
studi
use
pcr
establish
import
virus
etiolog
cap
consist
demonstr
virus
second
common
etiolog
factor
account
diagnos
case
recent
systemat
review
metaanalysi
viral
cap
signific
associ
viral
infect
increas
mortal
observ
mortal
increas
patient
bacterialvir
coinfect
howev
clinic
implic
debat
studi
perform
pcr
use
nasopharyng
oropharyng
swab
might
yield
neg
result
patient
lower
respiratori
tract
viral
infect
unlik
cap
viral
profil
clinic
implic
thereof
hcap
well
studi
therefor
perform
prospect
studi
investig
role
viral
infect
patient
hcap
cap
use
avail
adequ
respiratori
specimen
institut
identifi
season
variat
group
patient
studi
conduct
tertiari
referr
hospit
republ
korea
adult
patient
admit
hospit
hcap
cap
januari
decemb
prospect
recruit
provid
written
inform
consent
patient
exclud
studi
pneumonia
relat
wit
aspir
eat
vomit
obstruct
pneumonia
relat
airway
obstruct
tumor
hospitalacquir
hap
ventilatorassoci
pneumonia
vap
patient
undergo
microbiolog
studi
antibiot
administr
receiv
form
antibiot
hr
prior
hospit
refus
particip
studi
also
exclud
patient
multipl
pneumonia
episod
within
studi
period
first
pneumonia
episod
record
studi
approv
institut
review
board
ethic
committe
seoul
nation
univers
bundang
hospit
snubh
irb
conduct
complianc
declar
helsinki
pneumonia
defin
presenc
new
infiltr
chest
xray
along
suggest
sign
symptom
cough
sputum
fever
chill
dyspnea
pleurit
chest
pain
disturb
conscious
crackl
patient
hcap
fulfil
follow
receiv
intraven
therapi
home
receiv
wound
care
nurs
care
health
care
agenc
intraven
medic
therapi
day
pneumonia
attend
hemodialysi
clinic
receiv
intraven
chemotherapi
day
pneumonia
admit
hospit
day
day
pneumonia
resid
nurs
home
longterm
care
facil
patient
classifi
cap
fit
criteria
hcap
microbiolog
sampl
collect
within
hr
diagnosi
pneumonia
microbiolog
studi
includ
set
blood
cultur
sputum
endotrach
aspir
gram
stain
cultur
urinari
antigen
test
streptococcu
pneumonia
binax
inc
portland
pcr
test
mycoplasma
pneumonia
inhous
develop
nucleic
acid
sequenc
base
amplif
perform
indic
attend
physician
bronchoalveolar
lavag
bal
fluid
thoracentesi
conduct
indic
diagnosi
patient
test
respiratori
viru
multiplex
reversetranscript
pcr
rtpcr
use
avail
respiratori
specimen
patient
sputum
rtpcr
conduct
nasopharyng
specimen
respiratori
viru
multiplex
rtpcr
perform
accord
xtag
respiratori
viral
panel
rvp
assay
product
insert
instruct
luminex
molecular
diagnost
toronto
canada
consid
pneumonia
caus
specif
viru
respiratori
virus
detect
accept
respiratori
sampl
rtpcr
respiratori
sampl
consid
accept
polymorphonuclear
cell
fewer
squamou
squamou
epitheli
cell
observ
lowpow
magnif
observ
lowpow
magnif
unless
otherwis
specifi
result
express
mean
standard
deviat
sd
median
rang
continu
variabl
percentag
categor
variabl
student
ttest
use
compar
continu
variabl
chisquar
fisher
exact
test
use
compar
categor
variabl
variabl
p
univari
analysi
enter
multivari
logist
regress
analysi
identifi
independ
predictor
mortal
unless
otherwis
note
test
perform
signific
level
analys
perform
use
spss
ibm
corp
armonk
ny
usa
among
patient
visit
emerg
depart
due
pneumonia
studi
period
patient
diagnos
hcap
cap
fiftyf
patient
exclud
studi
microbiolog
specimen
obtain
prior
antibiot
administr
unaccept
n
due
overlap
particip
n
absenc
rtpcr
result
n
withdraw
inform
consent
n
fig
baselin
characterist
patient
hcap
patient
cap
patient
shown
tabl
convent
microbiolog
studi
includ
blood
cultur
sputum
endotrach
aspir
gram
stain
cultur
conduct
enrol
patient
administr
antibiot
within
hr
bal
conduct
patient
addit
diagnost
thoracentesi
perform
patient
proport
patient
underw
bal
thoracentesi
similar
cap
hcap
group
bal
vs
p
thoracentesi
vs
p
pathogen
relat
pneumonia
identifi
patient
among
patient
bacteri
pneumonia
patient
viral
patient
viralbacteri
coinfect
tabl
among
enrol
patient
patient
test
respiratori
virus
sputum
endotrach
aspir
remain
patient
underw
rtpcr
nasopharyng
specimen
addit
bal
fluid
rtpcr
perform
patient
patient
underw
pleural
effus
rtpcr
fiftyfour
patient
hcap
found
viral
infect
patient
pure
viral
infect
patient
viralbacteri
coinfect
cap
group
patient
viral
infect
viral
infect
rate
viralbacteri
coinfect
rate
respect
viral
infect
rate
significantli
lower
hcap
patient
cap
patient
irrespect
whether
viralbacteri
infect
includ
viral
infect
viralbacteri
coinfect
p
viral
infect
p
respiratori
virus
identifi
summar
tabl
hcap
cap
group
influenza
common
respiratori
viru
follow
enterorhinoviru
gener
viral
profil
patient
hcap
cap
similar
except
influenza
adenoviru
higher
cap
group
hcap
p
half
patient
hcap
receiv
antibiot
healthcar
facil
patient
cap
receiv
form
antibiot
prior
hospit
contrast
viral
infect
proport
bacteri
pneumonia
significantli
higher
patient
hcap
cap
vs
p
tabl
show
bacteri
pathogen
patient
hcap
cap
pseudomona
aeruginosa
methicillinresist
staphylococcu
aureu
mrsa
frequent
observ
hcap
cap
patient
p
p
respect
proport
multibacteri
multidrugresist
mdr
bacteri
infect
also
higher
hcap
cap
group
p
p
respect
empir
antimicrobi
treatment
regimen
hcap
cap
summar
tabl
season
distribut
pneumonia
fig
show
monthli
distribut
viral
bacteri
infect
hcap
group
bacteri
infect
predomin
season
common
februari
april
season
variat
curv
viral
infect
similar
cap
group
tendenc
lag
month
behind
cap
group
fig
show
distribut
viru
gener
viral
season
distribut
hcap
group
similar
cap
group
except
adenoviru
human
metapneumoviru
patient
influenza
pneumonia
half
histori
influenza
vaccin
median
length
hospit
stay
lo
rang
day
patient
hcap
significantli
longer
lo
patient
cap
vs
day
p
thirtyon
patient
die
hospit
hcap
group
higher
mortal
cap
group
studi
investig
microbiolog
profil
patient
hcap
focus
viral
infect
date
limit
studi
evalu
viral
profil
patient
hcap
howev
studi
includ
patient
sever
pneumonia
requir
icu
care
focus
cap
involv
limit
number
hcap
patient
furthermor
strictli
control
respiratori
sampl
time
specifi
whether
patient
receiv
antibiot
long
receiv
antibiot
prior
admiss
lastli
limit
respiratori
specimen
use
detect
respiratori
virus
mainli
nasopharyng
swab
therefor
gener
trend
microbiolog
profil
hcap
remain
unclear
present
studi
evalu
role
respiratori
virus
patient
mild
sever
hcap
comparison
patient
cap
use
avail
respiratori
specimen
includ
sputum
endotrach
aspir
bal
fluid
even
pleural
effus
unlik
previou
studi
microbiolog
result
show
differ
group
overal
viral
infect
rate
lower
hcap
group
cap
group
importantli
influenza
viral
infect
significantli
lower
patient
hcap
cap
p
sever
plausibl
explan
previou
multicent
studi
bronchial
asthma
odd
ratio
male
gender
age
year
independ
risk
factor
influenza
viral
pneumonia
moreov
chronic
lung
diseas
bronchial
asthma
chronic
obstruct
pulmonari
diseas
wellknown
risk
factor
viral
infect
studi
proport
male
similar
patient
cap
younger
therefor
male
gender
age
might
reason
patient
cap
higher
preval
chronic
lung
diseas
patient
hcap
therefor
cap
group
may
higher
chanc
infect
respiratori
virus
especi
influenza
furthermor
half
hcap
patient
hospit
day
day
pneumonia
therefor
may
littl
opportun
come
contact
patient
carri
respiratori
virus
similar
previou
studi
influenza
commonli
identifi
respiratori
viru
cap
patient
also
true
hcap
group
interestingli
half
patient
histori
influenza
vaccin
among
influenza
subtyp
detect
patient
influenza
subtyp
found
patient
particip
elderli
patient
mean
age
year
sever
studi
show
vaccin
efficaci
influenza
decreas
increas
age
although
sever
confound
factor
sinc
avail
data
vaccin
constitu
difficult
draw
conclus
efficaci
influenza
vaccin
studi
studi
requir
determin
relationship
effect
influenza
vaccin
age
studi
viral
pneumonia
found
affect
clinic
prognosi
lo
inhospit
mortal
either
group
recent
studi
cap
shown
similar
result
show
viral
infect
signific
associ
increas
mortal
patient
hcap
contradictori
previou
studi
report
viralbacteri
coinfect
import
risk
factor
mortal
cap
signific
differ
note
studi
previou
studi
obtain
sampl
pcr
via
nasopharyng
oropharyng
swab
may
lead
fals
result
case
viral
pneumonia
easier
access
tertiari
referr
hospit
due
healthcar
system
korea
might
anoth
reason
similar
prognosi
patient
viralbacteri
coinfect
viral
bacteri
infect
one
thing
mention
result
studi
interpret
caution
true
bacteri
profil
patient
known
present
studi
enrol
patient
receiv
antibiot
hr
prior
hospit
increas
yield
microbiolog
test
moreov
convent
microbiolog
studi
includ
blood
cultur
sputum
endotrach
aspir
gram
stain
cultur
conduct
within
hr
antibiot
administr
howev
obtain
low
rate
bacteri
detect
similar
previou
studi
bacteri
pathogen
identifi
patient
hcap
patient
cap
could
frailti
gram
stain
cultur
bacteri
detect
report
use
multibacteri
molecular
test
approach
approxim
doubl
pathogen
detect
patient
pneumonia
particularli
report
pcr
detect
significantli
haemophilu
influenza
streptococcu
pneumonia
moraxella
catarrhali
staphylococcu
aureu
escherichia
coli
klebsiella
pneumonia
standard
culturebas
method
studi
patient
patient
hcap
patient
cap
conduct
pcr
mycoplasma
pneumonia
two
patient
cap
show
posit
result
conduct
studi
accord
usual
clinic
practic
multibacteri
pcr
current
avail
hospit
howev
time
sensit
microbiolog
method
like
pcr
might
necessari
enabl
earli
bacteri
detect
pathogendirect
therapi
present
studi
mrsa
infect
strongest
predictor
inhospit
mortal
especi
hcap
patient
ci
p
adjust
age
sex
bmi
smoke
histori
ecog
statu
comorbid
actual
well
known
mrsa
pneumonia
result
numer
complic
high
mortal
rate
furthermor
resid
longterm
care
facil
identifi
risk
factor
mrsa
rather
hospit
prescript
antimicrobi
hospit
recent
studi
confirm
fact
studi
hcap
remov
updat
hapvap
guidelin
mani
studi
report
hcap
patient
infect
mdr
pathogen
howev
present
studi
hcap
patient
show
significantli
higher
mdr
bacteri
infect
rate
perform
multivari
analysi
adjust
age
sex
bmi
perform
statu
ecog
comorbid
pneumonia
sever
index
psi
curb
qsofa
found
hcap
import
predictor
mdro
ci
p
unlik
previou
studi
recent
number
elderli
patient
frequent
hospit
contact
increas
rapidli
mani
individu
resid
nurs
home
longterm
care
facil
especi
korea
hcap
patient
might
prone
mdr
bacteri
infect
recent
trend
may
explain
studi
shown
result
differ
previou
studi
howev
studi
updat
data
need
confirm
find
studi
sever
limit
first
limit
number
invas
respiratori
specimen
avail
studi
howev
bal
prefer
techniqu
invas
good
concord
found
result
cultur
sputum
transtrach
aspir
particularli
goodqual
sputum
specimen
obtain
studi
gram
stain
cultur
expector
sputum
produc
rel
high
yield
sputum
rtpcr
show
similar
effect
bal
fluid
rtpcr
second
includ
admit
patient
hcap
cap
pneumonia
patient
outpati
set
includ
previou
studi
includ
outpati
report
viral
pneumonia
rate
high
may
risk
result
underestim
proport
viral
pneumonia
lastli
studi
conduct
one
tertiari
referr
hospit
thu
may
reflect
limit
clinic
context
prospect
multicent
studi
hcap
cap
need
confirm
find
hcap
patient
lower
likelihood
viral
infect
similar
viral
profil
season
variat
patient
cap
viral
infect
affect
prognosi
patient
hcap
rather
multibacteri
mdr
bacteri
infect
import
concern
patient
hcap
support
inform
